Concepedia

Jayeta Chakrabarti

JC

Statistics

Publications

8

Citations

369

H-Index

8

Active since

2007

Affiliations

Pfizer (United States)(Current)

Pfizer (United Kingdom)

The University of Texas MD Anderson Cancer Center

Jayeta Chakrabarti is an author at Pfizer (United States) specializing in oncology, medicine, and cancer pharmacology.

Publications per year

2007–2023

8

Publications

8

Influence of Mammographic Parenchymal Pattern in Screening-Detected and Interval Invasive Breast Cancers on Pathologic Features, Mammographic Features, and Patient Survival

Gareth Porter, Andrew J. Evans, Eleanor Cornford et al. · American Journal of Roentgenology · 2007 · 111 citations

Medicine, Oncology, Pathology +17

Talazoparib in Patients with a Germline <i>BRCA</i>-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial

Sara A. Hurvitz, Anthony Gonçalvès, Hope S. Rugo et al. · The Oncologist · 2019 · 84 citations · Full text

Medicine, Oncology, Pharmacology +14

TALAPRO-3 Clinical Trial Protocol: Phase III Study of Talazoparib Plus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer

Neeraj Agarwal, Fred Saad, Arun Azad et al. · Future Oncology · 2023 · 40 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Neoadjuvant Talazoparib in Patients With Germline <i>BRCA1/2</i> Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study

Jennifer K. Litton, J. Thaddeus Beck, Jason M. Jones et al. · The Oncologist · 2023 · 39 citations · Full text

Medicine, Oncology, Pharmacology +16

Neoadjuvant talazoparib in patients with germline<i> BRCA1/2</i> (g<i>BRCA1/2</i>) mutation-positive, early HER2-negative breast cancer (BC): Results of a phase 2 study.

Jennifer K. Litton, J. Thaddeus Beck, Jason M. Jones et al. · Journal of Clinical Oncology · 2021 · 33 citations

Medicine, Oncology, Pharmacology +15

1–5 of 8